Enceladus Pharmaceuticals BV announces positive results from a phase 2a study in patients with active ulcerative colitis with Nanocort(R)

Enceladus Pharmaceuticals BV announces positive results from a phase 2a study in patients with active ulcerative colitis with Nanocort(R).

Click here for the press release.